Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Bucknelly21on Aug 24, 2022 12:12pm
68 Views
Post# 34917300

RE:RE:RE:RE:Long, very long

RE:RE:RE:RE:Long, very long

perfectly said 


Wino115 wrote:

I think we all agree on the view we would like to see much more insider buying, especially as they are nearing the second determination point with the oncology asset.

They need to understand better (and hopefully IR emphasizes this) that it is a very important signal to shareholders that any level of management is committed and is 100% aligned with its shareholders through the increasing ownership of managers who are paid out of shareholder owned corporate assets every year.

Like you say CanadaPiet, Levesque should know, or be told, that it's a waste of time and a deal breaker for him to go meet any new investors, asking them to buy shares because of the "bright future" when at the same time his General Counsel is selling his shares for "tax reasons" and those investors he is meeting see it reported. It's not hard to understand that dynamic and I'm sure it's part of the reason the level of belief behind THTX pipeline assets is so low, valuing them at zero now.  If the next round of options is also sold by GC and CMO and others anywhere in the mgmt structure, it will be a severely negative sign -tax reasons or not, so start saving your money for taxes!

Imagine if he could have told those investors that over the last 6 months all the board members upped their exposure beyond the free grants, his CMO, CFO and General Counsel all bought shares, some taking on mortgages or debt to do it, and so did he, and that no one has sold a share in the last year -only bought more.  THAT is showing commitment and that management actually believes the words they are all generously sharing to the market. I think the share would not be at 52 week lows if that was the case. The market would very clearly see that as a sign that things are moving in a positive way, well beyond the throw-away adjectives, toward derisking a massive potential asset for investors.  That would be an anchor of value for the company as opposed to this slow leak they've had for the better part of 6 months that has sunk the pipeline ship.

They must know that if they say everything looks amazing, the market doesn't believe them as the only way to actually prove that fact to the market is through a highly committed personal investment - putting money where your mouth is.  And it's only been lukewarm at best. At next blackout period expiry, it's put up or shut up for management on the pipeline assets. Either you commit meaningfully because you see the clear opportunity to multiply your investment soon, or you stop the hollow superlatives touted at investor conferences which no one is believing at this point. If not, then we realize we are the chumps.

 

canadapiet wrote:

 

Ok, respect your view ........and it must be surely a difficult way in "oncology" trials, so many things to take account of.
But other companies are far more "open"(what is IR doing over there????)  and trials are going much smoother(mostly because of partnering with a bigger pharma), they are in better financial condition AND .........INSIDERS are far more involved/invested!!!!! 

Give me a good reason why they are telling us all those years the shareprice is way to low, no.........RIDICULOUS low, they see "good things" in trials etc, but investing some of their money????????..............HELL NO!!!!!!!
 

 



<< Previous
Bullboard Posts
Next >>